Continuous glucose monitoring for all patients
In a six-month trial sponsored by device maker Dexcom, 283 adults with type 2 diabetes not using insulin received either the Dexcom G7, a coin-size disc worn on the upper arm, or routine care. The main results include:
- Average HbA1c fell from 8.8% to 7.2% in the monitoring group, compared with a drop from 8.7% to 8.0% in the routine-care group.
- Device users spent about five more hours a day with blood sugar in the 70–180 mg/dL target range.
- The benefit was consistent regardless of age, sex, race, body mass index, income, education or medications; 97% of participants were still using the monitors at the end of the study.
Study leader Dr. Roy Beck of the Jaeb Center for Health Research in Florida said the consistent benefit supports considering the devices much earlier in type 2 diabetes care, before insulin is needed. It is worth noting that the study was sponsored by the device manufacturer.
A new pill for ulcerative colitis
Johnson & Johnson’s pill Icotyde (icotrokinra), already used for psoriasis, significantly outperformed a placebo in a mid-stage trial of 252 patients with moderate to severe ulcerative colitis. It is the first oral peptide that blocks the interleukin-23 protein, whereas previous drugs with this mechanism had to be given intravenously.

















